Endovasc Inc.(fka EVSC)

[Drugdoctor]

Proof of the FRAUD called Endovasc!

(This is a repost of a post that has been around for years, but since it is all truth, it never seems to go away, lol)


Jan. 1998 NEWSLETTER (from ENDOVASC WEBSITE!!!)

Don't bother trying the links.. Endovasc REMOVED this info from its website! Wonder why!

Some of this info is a REPOST of info previously posted here


Future Plans

After achieving FDA approval, Endovasc plans to launch our first product. This should be accomplished before year end. We will keep you updated on the progress.

1998 will be a great year for Endovasc, its associates, and shareholders. We look forward to our continued success together..

http://www.endovasc.com/html/newsletters/vol1/newslettervol1a.html


July 1999, Endovasc NEWSLETTER


PROGRESS REPORT

Phase I Clinical Trials are ready to begin at the University of Texas Health Science Center, Houston with Richard Smalling, MD, PhD.

FUTURE PLANS

FDA approval is imminent —

http://www.endovasc.com/html/newsletters/vol2/newslettervol2a.html

October 1999- NEWSLETTER on ENDV WEBSITE


We are delighted that the FDA did not ask us to perform additional safety and efficacy experiments for Liprostin™," said company Chief Operating Officer, Gary R. Ball. "We will file our application by the end of November." The Company said that it will begin simultaneous trials in Europe aimed at producing market approval and revenues in 2000. "We have collaborations ongoing that are producing small revenues," said Mr. Ball, "but we look for the Company to break even from sales of Liprostin™ as early as June of next year."


http://www.endovasc.com/html/newsletters/vol3/newslettervol3a.html


Liprostin™ (liposomal prostaglandin E1) Currently in clinical trials for the treatment of peripheral arterial occlusive disease (PAOD) and the treatment of critical limb ischemia. Mfg: Endovasc Ltd., Inc. Source: PR Newswire - 11/04/99.


(this link works)
http://mtdesk.com/l.shtml

I don't think so, eh DUKTUR????


Newsletter - Jan. 2000 Endovasc Website!

What is the latest time frame for the clinical trials and how close are they to completion? Once completed, is there an estimated time to production? The time line for clinical trials has been greatly affected by the FDA's waiver of Phase I & II trials. With the advent of Phase III trials, the projections for size of trials, number of sites for trials, and funds required to conduct these trials are all being discussed, identified, and developed so that Phase III can begin within this first calendar quarter of 2000. Ideally, completion and subsequent FDA approval would come at the end of this year.


http://www.endovasc.com/html/newsletters/Vol4/newslettervol4a.html

April 2000 - Endovasc Newsletter- Endv- WEBSITE!


The patented field of use for Liprostin™ in treating various vascular dysfunctions and nicotine (NRA), which is a world-wide exclusive gives the company a very unique and competitive edge. Liprostin™ will be available for clinical trials in the Summer of 2000 and is expected to be available for the first FDA approved indication in the Summer of 2001.


http://www.endovasc.com/html/newsletters/Vol5/newslettervol5.html


This from the same April 2000 NEWSLETTER!


FREQUENTLY ASKED QUESTIONS

What is the status of the SEC response filing? When will the company return to OTC? Will the company trade on NASDAQ? The SEC has now indicated they are satisfied. The company has filed the new form 15c211 to resume re-listing on the Over The Counter Bulletin Board (OTCBB), with approval expected within days. Once the Company has completed the pending financing, the decision will be made when to apply to NASDAQ.



Will clinical trials start on the nicotine agent, and when? Yes, the company intends to commence human trials of NRA (nicotine receptor agonist) in early 2001. The protocol for Ischemia trials on rabbit limb is being developed. The length of the trial should be approximately 6 weeks.



When does the company expect to have FDA approval and a product to market? The company projects that Phase III clinical trials will begin in this quarter and that there will be review and approval by the Federal Drug Administration (FDA) of Liprostin™ in the Summer of 2001


Quarter Ending: Dec 31 1999

Authorized Shares of Common Stock: 100M

Common Stock Shares Issued 10.7M

Outstanding shares of Common Stock at Qtr. End 8.1M

Treasury Stock 2.6M

Transfer Agent: Nevada Agency & Trust Co.

Shareholders: Approx. 100


Why has there been such a significant drop in the stock price? What you are seeing with the stock price is a combination of market shorting and the recent investor flight from small cap companies to "blue chips" caused by the current uncertainty in the stock market. This is not a long-term phenomenon. With the progress continually being made by the company, recovery is expected.


May 2000- NEWSLETTER


Research & Development
By Dr. Diane Dottavio


Liprostin™
The completion of the Chemistry, Manufacturing and Controls (CMC) manufacturing requirements for Liprostin™ by Collaborative BioAlliance, Inc. completes Endovasc's Investigational New Drug (IND) application requirements for the Food and Drug Administration (FDA). We now have the drug ready to begin clinical trials for critical limb ischemia. We expect to submit our IND for critical limb ischemia in June and with timely FDA response, will commence clinical trials in September.




NRA
Animal studies with the nicotine receptor agonist (NRA) will begin soon. Human trials of NRA are anticipated to begin in 2002. Please note that in last month's newsletter in the "Frequently asked Questions" section there was a typographical error which indicated these human studies were expected to begin in early 2001. We apologize for the error. Dr. Cooke and his team are in final preparations to begin animal studies at Stanford University.


http://www.endovasc.com/html/newsletters/vol6/newslettervol6a.html

And June 2000, they were saying in the NEWSLETTER


FREQUENTLY ASKED QUESTIONS

Question: What does the recently filed, SB-2 secondary public offering do to our investment? And what will this do to the chances of going on the Nasdaq small cap?
Answer : Although the conversion of the Preferred Stock will be somewhat diluted, it should help your investment by substantially increasing the trading volume. The net result could be an increase in the share price. It should also greatly improve an earlier move to the Nasdaq since one of the requirements is a larger shareholder base than the Company now has.

http://www.endovasc.com/html/newsletters/vol7/newslettervol7b.html

And July-August Newsletter 2000- A DISCLAIMER APPEARS!

Any forward-looking statements contained herein are based on the company's historical performance. They are subject to various risks and uncertainties detailed from time to time in the company's filings with Securities and Exchange Commission and may not be evident at the time of this release.




http://www.endovasc.com/html/newsletters/vol8/newslettervol8d.html

Q&A | June2001 | page [1]


QUESTION 6/20/01 - Is ENDV dropping like a stone because discount convertible preferred holders in the Camen Islands are shorting the #### out of it against the box? In other words is ENDV really legit... I am asking myself, or did I get scammed?

ANSWER - ENDV is a legitimate company which operates from offices in Montgomery,Texas. ENDV continues to meet the SEC guidelines for reporting and those reports can be accessed on the SEC website. Unfortunately, the OTC is a risky place to be both as an investor and a company. Which is why listing on Nasdaq continues to be a goal of ENDV.

ROFLMFAO - WOW- they are telling you you are risking your money! Sure they are meeting reporting requirements, as they DILUTE THE HEII out of your stock equity!


QUESTION 6/5/01 - What is your information about your stock, outstanding? It would be great to know so that I know when I buy more shares or more. Do you know if any shares have been shorted and if yes how many?? What are the chances of the company to succeed in these hot item topics??

ANSWER - Common Stock = 100M shares authorized
approximately 22.5M shares outstanding
Preferred stock= 20M authorized
16K & 15K shares series A 8% convertible preferred = issued and outstanding
The company has enough money to take it through the end of the year with additional funding available through the series A, 8% convertible preferred. The company is also seeking additional funding in the amount of up to $10M to continue to support clinical trials for Liprostin, as well as the research & development of NRA, stent coating, and resorbable/biodegradable stent products.

WOW- 10 million more needed- wow- Now that is NEWS! I estimate at least 100 million more shares, probably more, to raise that kind of money through the OFFSHORE FINANCE COMPANIES!


QUESTION 6/4/01 - Will your company be going to the Nasdaq?

ANSWER - Listing on Nasdaq has been a corporate goal for some time. As we become able to meet the criteria for Nasdaq listing, the company plans to make necessary application for listing.




And Sept. 2001 ENDV NEWSLETTER



After reviewing the data from the successful Phase I study, the Company determined to proceed with the Phase III clinical studies as earlier suggested by the FDA.
Phase III clinical studies, scheduled for November, 2001, are focused on patients who have lost circulation in their lower limbs (critical limb ischemia or CLI) and are in danger of requiring amputation.
July 25, 2001 Liprostin™ application for Orphan Drug status was submitted to FDA


http://www.endovasc.com/html/newsletters/vol11/newslettervol11.html


And suddenly SEPT. 2001 the TIMELINES CHANGED?? ENDV NEWSLETTER

Q. What is the tentative date for the completion of your Phase III trials?

A. Our Liprostin™ clinical trials are scheduled to begin in November of this year and completion is anticipated by the end of 2003 or early 2004. Nothing can be taken for granted and nothing left undone to make sure that we have the best and safest product available. Please monitor our web page for updates on our product development and clinical trials schedules.

http://www.endovasc.com/html/newsletters/vol11/newslettervol11c.html


And what are they saying now?

Q&A | page [1-2]

QUESTION 02/06/02 - When do you see your first product hitting the market?

ANSWER - We anticipate initiating Phase III clinical trials for both Liprostin™ and NRA in the first half of 2002. It will take approximately 24 to 36 months to complete these Phase III clinical trials depending on how quickly patients are enrolled into the trial.




QUESTION 02/06/02 - Why is your stock price going down?

ANSWER - We do not understand the decline in our stock price. However, we can assure you that Endovasc complies with SEC guidelines regarding the timely dissemination of material news.




QUESTION 02/06/02 - How many shares of common stock are outstanding? I'm interested in learning more about apparent dilution?

ANSWER - For information about Endovasc securities, we would refer you to our SEC filings. Our Form 10-Q for the period ended September 30, 2001, showed that there were 61,783,832 shares issued and 40,253,331 shares outstanding of our common stock. For that same period, there were 15,760 shares of Series A 8% cumulative convertible preferred stock issued and outstanding. The deadline for filing our Form 10-Q for the period ending December 31, 2001 is February 15, 2002.


http://www.endovasc.com/html/Q-A/feb-2002.html

ROFLMFAO at the above answer! They had answered the question the month before!!! Why not continue to answer truthfully?


Q&A | page [1]

QUESTION 01/14/02 - What is the total number of outstanding shares in the company? The float?

ANSWER - Approximately 80MM with insiders owning approximately 20%

http://www.endovasc.com/html/Q-A/jan-2002.html

-----------------------------------------------------------

This is what they originally said on July 26th, 2002 and then modified after Colombia complained, on August 1, 2002!

Trials at Columbia University demonstrated that -- using Endovasc's treatment, 80% of test animals with an artificially-induced heart failure grew new blood vessels and heart tissue to replace the damaged part of their hearts, regaining heart function. The Company said Stanford researchers found stem cell replacement tissues in previous animal models of ischemia and the restoration of cardiac function found in the heart-failure model at Columbia may be more than angiogenesis -- it might be a combination of new blood vessel growth and endogenous stem cells making new heart muscle cells. This re-growth of the heart tissue and restoration of cardiac function would explain a process is called Cardiogenesis ... the actual renewal of the heart.


Now, this is what they say in the latest pump, about Colombia's trials...

During tests at Columbia University, the drug helped improve blood flow in animals after the researchers artificially induced ischemia in the animals

A far cry from "regaining heart function"

And Aug. 13, 2002 PRESS RELEASE!! PUMPING NICOTINE for WHAT?


"Company officials are hoping to gain approval of the drug as a neutraceutical -- a food or beverage with health applications -- within the next few months, which would allow Angiogenix to be developed as a drink, patch or other over-the-counter product for use in building muscle mass".

...According to a statement, Endovasc officials said they hope to begin testing Angiogenix for use in repairing damaged hearts by the fourth quarter of this year with about 75 patients at the Arizona Heart Institute in Phoenix and possibly the Texas Heart Institute in Houston



FOLKS- I PRESENT THIS INFORMATION TO YOU TO SHOW A CONTINUOUS PATTERN OF LIES AND DECEPTION BY THIS COMPANY TO INVESTORS... NOTHING THEY HAVE PROJECTED IN THE ABOVE HYPE AND PUMP HAS COME TRUE, IMO!!!!